{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T15:24:22Z","timestamp":1772119462742,"version":"3.50.1"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T00:00:00Z","timestamp":1766102400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T00:00:00Z","timestamp":1766102400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s00520-025-10243-z","type":"journal-article","created":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T08:13:11Z","timestamp":1766131991000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Does pre-checkpoint inhibitor sarcopenia, visceral, or subcutaneous fat predict survival in non-small cell lung cancer patients?"],"prefix":"10.1007","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-3113-3298","authenticated-orcid":false,"given":"Julia","family":"Kooser","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mellar","family":"Davis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tian","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erin","family":"Vanenkevort","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amanda","family":"Young","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicole","family":"Koppenhaver","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Braxton","family":"Lagerman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mudit","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aalpen","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Wojtowicz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,19]]},"reference":[{"issue":"8","key":"10243_CR1","doi-asserted-by":"publisher","first-page":"2920","DOI":"10.1158\/1078-0432.CCR-08-2242","volume":"15","author":"CM Prado","year":"2009","unstructured":"Prado CM, Baracos VE, McCargar LJ et al (2009) Sarcopenia as a determinant of chemotherapy toxicity and time to tumor progression in metastatic breast cancer patients receiving capecitabine treatment. Clin Cancer Res 15(8):2920\u20132926. https:\/\/doi.org\/10.1158\/1078-0432.CCR-08-2242","journal-title":"Clin Cancer Res"},{"issue":"23","key":"10243_CR2","doi-asserted-by":"publisher","first-page":"9268","DOI":"10.3390\/ijms21239268","volume":"21","author":"VS Armstrong","year":"2020","unstructured":"Armstrong VS, Fitzgerald LW, Bathe OF (2020) Cancer-associated muscle wasting\u2014candidate mechanisms and molecular pathways. Int J Mol Sci 21(23):9268","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10243_CR3","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1038\/bjc.2017.149","volume":"117","author":"M Ebadi","year":"2017","unstructured":"Ebadi M, Martin L, Ghosh S et al (2017) Subcutaneous adiposity is an independent predictor of mortality in cancer patients. Br J Cancer 117(1):148\u2013155. https:\/\/doi.org\/10.1038\/bjc.2017.149","journal-title":"Br J Cancer"},{"issue":"6","key":"10243_CR4","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1001\/jamaoncol.2024.1120","volume":"10","author":"TL Chaunzwa","year":"2024","unstructured":"Chaunzwa TL, Qian JM, Li Q et al (2024) Body composition in advanced non-small cell lung cancer treated with immunotherapy. JAMA Oncol 10(6):773\u2013783. https:\/\/doi.org\/10.1001\/jamaoncol.2024.1120","journal-title":"JAMA Oncol"},{"key":"10243_CR5","doi-asserted-by":"publisher","first-page":"1368966","DOI":"10.3389\/fnut.2024.1368966","volume":"11","author":"M Alser","year":"2024","unstructured":"Alser M, Naja K, Elrayess MA (2024) Mechanisms of body fat distribution and gluteal-femoral fat protection against metabolic disorders. Front Nutr 11:1368966. https:\/\/doi.org\/10.3389\/fnut.2024.1368966","journal-title":"Front Nutr"},{"key":"10243_CR6","doi-asserted-by":"publisher","DOI":"10.3390\/ijms18061321","author":"AE Achari","year":"2017","unstructured":"Achari AE, Jain SK (2017) Adiponectin, a therapeutic target for obesity, diabetes, and endothelial dysfunction. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms18061321","journal-title":"Int J Mol Sci"},{"issue":"4","key":"10243_CR7","doi-asserted-by":"publisher","first-page":"851","DOI":"10.5114\/aoms.2016.58928","volume":"13","author":"MS Ellulu","year":"2017","unstructured":"Ellulu MS, Patimah I, Khaza\u2019ai H, Rahmat A, Abed Y (2017) Obesity and inflammation: the linking mechanism and the complications. Arch Med Sci 13(4):851\u2013863. https:\/\/doi.org\/10.5114\/aoms.2016.58928","journal-title":"Arch Med Sci"},{"issue":"4","key":"10243_CR8","doi-asserted-by":"publisher","first-page":"739","DOI":"10.5114\/aoms.2014.44865","volume":"10","author":"N K\u00f6\u015f\u00fc\u015f","year":"2014","unstructured":"K\u00f6\u015f\u00fc\u015f N, K\u00f6\u015f\u00fc\u015f A, Turhan N (2014) Relation between abdominal subcutaneous fat tissue thickness and inflammatory markers during pregnancy. Arch Med Sci 10(4):739\u2013745. https:\/\/doi.org\/10.5114\/aoms.2014.44865","journal-title":"Arch Med Sci"},{"key":"10243_CR9","doi-asserted-by":"publisher","first-page":"200210","DOI":"10.1016\/j.hnm.2023.200210","volume":"33","author":"S Bansal","year":"2023","unstructured":"Bansal S, Vachher M, Arora T, Kumar B, Burman A (2023) Visceral fat: a key mediator of NAFLD development and progression. Human Nutrition & Metabolism 33:200210. https:\/\/doi.org\/10.1016\/j.hnm.2023.200210","journal-title":"Human Nutrition & Metabolism"},{"key":"10243_CR10","doi-asserted-by":"publisher","DOI":"10.3390\/nu13062101","author":"L Crudele","year":"2021","unstructured":"Crudele L, Piccinin E, Moschetta A (2021) Visceral adiposity and cancer: role in pathogenesis and prognosis. Nutrients. https:\/\/doi.org\/10.3390\/nu13062101","journal-title":"Nutrients"},{"issue":"3","key":"10243_CR11","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/j.ajcnut.2023.07.001","volume":"118","author":"L Li","year":"2023","unstructured":"Li L, Li W, Xu D et al (2023) Association between visceral fat area and cancer prognosis: a population-based multicenter prospective study. Am J Clin Nutr 118(3):507\u2013517. https:\/\/doi.org\/10.1016\/j.ajcnut.2023.07.001","journal-title":"Am J Clin Nutr"},{"key":"10243_CR12","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/5215915","volume":"2022","author":"Z Zhang","year":"2022","unstructured":"Zhang Z, Zhang C, Zhang S (2022) Irisin activates M1 macrophage and suppresses Th2-type immune response in rats with pelvic inflammatory disease. Evid Based Complement Alternat Med 2022:5215915. https:\/\/doi.org\/10.1155\/2022\/5215915","journal-title":"Evid Based Complement Alternat Med"},{"issue":"2","key":"10243_CR13","first-page":"243","volume":"68","author":"AI Mazur-Bialy","year":"2017","unstructured":"Mazur-Bialy AI, Bilski J, Pochec E, Brzozowski T (2017) New insight into the direct anti-inflammatory activity of a myokine irisin against proinflammatory activation of adipocytes. Implication for exercise in obesity. J Physiol Pharmacol. 68(2):243\u2013251","journal-title":"J Physiol Pharmacol."},{"issue":"3","key":"10243_CR14","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1016\/j.bbrc.2016.12.084","volume":"485","author":"L Shao","year":"2017","unstructured":"Shao L, Li H, Chen J et al (2017) Irisin suppresses the migration, proliferation, and invasion of lung cancer cells via inhibition of epithelial-to-mesenchymal transition. Biochem Biophys Res Commun 485(3):598\u2013605. https:\/\/doi.org\/10.1016\/j.bbrc.2016.12.084","journal-title":"Biochem Biophys Res Commun"},{"key":"10243_CR15","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.127901","author":"Q Jia","year":"2019","unstructured":"Jia Q, Wang J, He N, He J, Zhu B (2019) Titin mutation associated with responsiveness to checkpoint blockades in solid tumors. JCI Insight. https:\/\/doi.org\/10.1172\/jci.insight.127901","journal-title":"JCI Insight"},{"key":"10243_CR16","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.761758","volume":"9","author":"X Xie","year":"2021","unstructured":"Xie X, Tang Y, Sheng J et al (2021) Titin mutation is associated with tumor mutation burden and promotes antitumor immunity in lung squamous cell carcinoma. Front Cell Dev Biol 9:761758. https:\/\/doi.org\/10.3389\/fcell.2021.761758","journal-title":"Front Cell Dev Biol"},{"issue":"2","key":"10243_CR17","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1080\/01635581.2022.2153879","volume":"75","author":"B Ren","year":"2023","unstructured":"Ren B, Shen J, Qian Y, Zhou T (2023) Sarcopenia as a determinant of the efficacy of immune checkpoint inhibitors in non-small cell lung cancer: a meta-analysis. Nutr Cancer 75(2):685\u2013695. https:\/\/doi.org\/10.1080\/01635581.2022.2153879","journal-title":"Nutr Cancer"},{"key":"10243_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.nut.2021.111345","volume":"90","author":"HY Deng","year":"2021","unstructured":"Deng HY, Chen ZJ, Qiu XM, Zhu DX, Tang XJ, Zhou Q (2021) Sarcopenia and prognosis of advanced cancer patients receiving immune checkpoint inhibitors: a comprehensive systematic review and meta-analysis. Nutrition 90:111345. https:\/\/doi.org\/10.1016\/j.nut.2021.111345","journal-title":"Nutrition"},{"key":"10243_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2020.106907","volume":"88","author":"J Wang","year":"2020","unstructured":"Wang J, Cao L, Xu S (2020) Sarcopenia affects clinical efficacy of immune checkpoint inhibitors in non-small cell lung cancer patients: a systematic review and meta-analysis. Int Immunopharmacol 88:106907. https:\/\/doi.org\/10.1016\/j.intimp.2020.106907","journal-title":"Int Immunopharmacol"},{"key":"10243_CR20","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.lungcan.2020.03.003","volume":"143","author":"B Roch","year":"2020","unstructured":"Roch B, Coffy A, Jean-Baptiste S et al (2020) Cachexia - sarcopenia as a determinant of disease control rate and survival in non-small lung cancer patients receiving immune-checkpoint inhibitors. Lung Cancer 143:19\u201326. https:\/\/doi.org\/10.1016\/j.lungcan.2020.03.003","journal-title":"Lung Cancer"},{"issue":"5","key":"10243_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e27282","volume":"10","author":"Y Feng","year":"2024","unstructured":"Feng Y, Wang L, Guo F et al (2024) Predictive impact of sarcopenia in advanced non-small cell lung cancer patients treated with immune checkpoint inhibitors: a retrospective study. Heliyon 10(5):e27282. https:\/\/doi.org\/10.1016\/j.heliyon.2024.e27282","journal-title":"Heliyon"},{"issue":"1","key":"10243_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-29825-5","volume":"8","author":"BA Derstine","year":"2018","unstructured":"Derstine BA, Holcombe SA, Ross BE, Wang NC, Su GL, Wang SC (2018) Skeletal muscle cutoff values for sarcopenia diagnosis using T10 to L5 measurements in a healthy US population. Sci Rep 8(1):11369. https:\/\/doi.org\/10.1038\/s41598-018-29825-5","journal-title":"Sci Rep"},{"issue":"2","key":"10243_CR23","doi-asserted-by":"publisher","DOI":"10.2214\/ajr.25.32781","volume":"225","author":"C Ju","year":"2025","unstructured":"Ju C, Yao L, Yoon SY et al (2025) Defining reference values for skeletal muscle metrics on abdominal CT using data from healthy young adult populations: a systematic review and meta-analysis. AJR Am J Roentgenol 225(2):e2532781. https:\/\/doi.org\/10.2214\/ajr.25.32781","journal-title":"AJR Am J Roentgenol"},{"key":"10243_CR24","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11123500","author":"D Portal","year":"2022","unstructured":"Portal D, Melamed G, Segal G, Itelman E (2022) Sarcopenia as manifested by L3SMI is associated with increased long-term mortality amongst internal medicine patients-a prospective cohort study. J Clin Med. https:\/\/doi.org\/10.3390\/jcm11123500","journal-title":"J Clin Med"},{"issue":"9","key":"10243_CR25","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1038\/s41430-020-0628-1","volume":"74","author":"AJ Woodward","year":"2020","unstructured":"Woodward AJ, Avery A, Keating SE, Ward LC, Coombes JS, Macdonald GA (2020) Computerised tomography skeletal muscle and adipose surface area values in a healthy Caucasian population. Eur J Clin Nutr 74(9):1276\u20131281. https:\/\/doi.org\/10.1038\/s41430-020-0628-1","journal-title":"Eur J Clin Nutr"},{"issue":"Sep","key":"10243_CR26","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1038\/s41430-020-0628-1","volume":"74","author":"AJ Woodward","year":"2020","unstructured":"Woodward AJ, Avery A, Keating SE, Ward LC, Coombes JS, Macdonald GA (2020) Computerised tomography skeletal muscle and adipose surface area values in a healthy Caucasian population. Eur J Clin Nutr 74(Sep):1276\u20131281. https:\/\/doi.org\/10.1038\/s41430-020-0628-1","journal-title":"Eur J Clin Nutr"},{"issue":"6","key":"10243_CR27","doi-asserted-by":"publisher","first-page":"2898","DOI":"10.1002\/jcsm.13367","volume":"14","author":"JH Lee","year":"2023","unstructured":"Lee JH, Kang D, Ahn JS, Guallar E, Cho J, Lee HY (2023) Obesity paradox in patients with non-small cell lung cancer undergoing immune checkpoint inhibitor therapy. J Cachexia Sarcopenia Muscle 14(6):2898\u20132907","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"1","key":"10243_CR28","doi-asserted-by":"publisher","first-page":"9","DOI":"10.14740\/wjon1225","volume":"11","author":"S Minami","year":"2020","unstructured":"Minami S, Ihara S, Tanaka T, Komuta K (2020) Sarcopenia and visceral adiposity did not affect efficacy of immune-checkpoint inhibitor monotherapy for pretreated patients with advanced non-small cell lung cancer. World J Oncol 11(1):9\u201322","journal-title":"World J Oncol"},{"key":"10243_CR29","doi-asserted-by":"publisher","DOI":"10.3389\/fnut.2022.900823","volume":"9","author":"S Li","year":"2022","unstructured":"Li S, Liu Z, Ren Y et al (2022) Sarcopenia was a poor prognostic predictor for patients with advanced lung cancer treated with immune checkpoint inhibitors. Front Nutr 9:900823","journal-title":"Front Nutr"},{"key":"10243_CR30","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.726257","volume":"11","author":"S Li","year":"2021","unstructured":"Li S, Wang T, Tong G, Li X, You D, Cong M (2021) Prognostic impact of sarcopenia on clinical outcomes in malignancies treated with immune checkpoint inhibitors: a systematic review and meta-analysis. Front Oncol 11:726257","journal-title":"Front Oncol"},{"issue":"2","key":"10243_CR31","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1080\/01635581.2022.2153879","volume":"75","author":"B Ren","year":"2023","unstructured":"Ren B, Shen J, Qian Y, Zhou T (2023) Sarcopenia as a determinant of the efficacy of immune checkpoint inhibitors in non-small cell lung cancer: a meta-analysis. Nutr Cancer 75(2):685\u2013695","journal-title":"Nutr Cancer"},{"key":"10243_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2020.106907","volume":"88","author":"J Wang","year":"2020","unstructured":"Wang J, Cao L, Xu S (2020) Sarcopenia affects clinical efficacy of immune checkpoint inhibitors in non-small cell lung cancer patients: a systematic review and meta-analysis. Int Immunopharmacol 88:106907","journal-title":"Int Immunopharmacol"},{"issue":"6","key":"10243_CR33","doi-asserted-by":"publisher","first-page":"2591","DOI":"10.1002\/jcsm.13333","volume":"14","author":"J Tao","year":"2023","unstructured":"Tao J, Fang J, Chen L et al (2023) Increased adipose tissue is associated with improved overall survival, independent of skeletal muscle mass in non-small cell lung cancer. J Cachexia Sarcopenia Muscle 14(6):2591\u20132601. https:\/\/doi.org\/10.1002\/jcsm.13333","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"3","key":"10243_CR34","doi-asserted-by":"publisher","first-page":"e213520","DOI":"10.1001\/jamanetworkopen.2021.3520","volume":"4","author":"F Petrelli","year":"2021","unstructured":"Petrelli F, Cortellini A, Indini A et al (2021) Association of obesity with survival outcomes in patients with cancer: a systematic review and meta-analysis. JAMA Netw Open 4(3):e213520\u2013e213520. https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.3520","journal-title":"JAMA Netw Open"},{"issue":"8","key":"10243_CR35","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1016\/j.jtho.2021.04.020","volume":"16","author":"J Barbi","year":"2021","unstructured":"Barbi J, Patnaik SK, Pabla S et al (2021) Visceral Obesity Promotes Lung Cancer Progression-Toward Resolution of the Obesity Paradox in Lung Cancer. J Thorac Oncol 16(8):1333\u20131348. https:\/\/doi.org\/10.1016\/j.jtho.2021.04.020","journal-title":"J Thorac Oncol"},{"issue":"1","key":"10243_CR36","doi-asserted-by":"publisher","DOI":"10.1186\/1758-5996-3-12","volume":"3","author":"CL Donohoe","year":"2011","unstructured":"Donohoe CL, Doyle SL, Reynolds JV (2011) Visceral adiposity, insulin resistance and cancer risk. Diabetol Metab Syndr 3(1):12. https:\/\/doi.org\/10.1186\/1758-5996-3-12","journal-title":"Diabetol Metab Syndr"},{"key":"10243_CR37","doi-asserted-by":"publisher","unstructured":"AR. (1996) A simulation study of the number of events per variable in logistic regression analysis. J Clin Epidemiol. 49(12):1373\u20139. https:\/\/doi.org\/10.1016\/s0895-4356(96)00236-3","DOI":"10.1016\/s0895-4356(96)00236-3"},{"issue":"2","key":"10243_CR38","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1016\/j.ajcnut.2025.05.022","volume":"122","author":"CM Prado","year":"2025","unstructured":"Prado CM, Gonzalez MC, Norman K et al (2025) Methodological standards for body composition\u2014an expert-endorsed guide for research and clinical applications: levels, models, and terminology. Am J Clin Nutr 122(2):384\u2013391. https:\/\/doi.org\/10.1016\/j.ajcnut.2025.05.022","journal-title":"Am J Clin Nutr"},{"issue":"11","key":"10243_CR39","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.1111\/1759-7714.13958","volume":"12","author":"J Lee","year":"2021","unstructured":"Lee J, Kim EY, Kim E, Kim KG, Kim YJ, Kim YS, Ahn HK, Lee SW (2021) Longitudinal changes in skeletal muscle mass in patients with advanced squamous cell lung cancer. Thorac Cancer 12(11):1662\u20131667. https:\/\/doi.org\/10.1111\/1759-7714.13958","journal-title":"Thorac Cancer"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-025-10243-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-025-10243-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-025-10243-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T08:47:50Z","timestamp":1768985270000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-025-10243-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,19]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["10243"],"URL":"https:\/\/doi.org\/10.1007\/s00520-025-10243-z","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-5389970\/v1","asserted-by":"object"}]},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,19]]},"assertion":[{"value":"4 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This is a retrospective study and does not include live subjects. The study was reviewed by Geisinger Medical Center\u2019s IRB and received exemption status.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The study received IRB exemption status. Patient identifiers were sequestered and not provided.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The study received IRB exemption status. Patient identifiers were sequestered and not provided.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"46"}}